Neratinib tablets
Sponsors
Convalife (Shanghai) Co., Ltd.
Conditions
Advanced Solid TumorNSCLC
Phase 2
Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations
NCT06029816
Start: 2023-11-20End: 2025-12-30Target: 42Updated: 2023-09-08
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Not yet recruitingNCT06519110
Start: 2024-08-10End: 2026-04-15Target: 60Updated: 2024-07-25